Dabrafenib plus Trametinib Is Active in BRAFV600E Anaplastic Thyroid Cancer [Research Watch]

Dual BRAF/MEK inhibition achieves responses in 69% of BRAFV^600E anaplastic thyroid cancers (ATC).

from Cancer via ola Kala on Inoreader http://ift.tt/2jgMCeh
via IFTTT